What is Travere Therapeutics, Inc.'s earnings per share (EPS)?

Travere Therapeutics, Inc. (TVTX) reported diluted earnings per share of -$0.29 for fiscal year 2025. This represents a 92.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Travere Therapeutics, Inc. (TVTX) Financials

TVTX

Trailing 12 months to June 30, 2026

Revenue $591.3M +77.1% YoY

Net Income -$43.5M +74.3% YoY

EPS (Diluted) -$0.46 +77.2% YoY

Operating Cash Flow $92.7M +180.3% YoY

Market Cap $5.4B as of Oct 2, 2026

Price / Sales 9.1x on $591.3M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 219x on $24.5M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 2, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 4, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TVTX SEC filings page.

Travere Therapeutics, Inc. (TVTX) reported $591.3M in revenue over the twelve months to Jun 30, 2026, up 77.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TVTX FY2025 2026-08-29

Revenue scaling is absorbing fixed costs, while cash conversion turns positive before reported profitability and leaves a liability-heavy balance sheet.

From FY2024 to FY2025, revenue more than doubled while operating margin improved from -138.9% to -12.8%; with gross margin broadly stable, the improvement points to fixed-cost absorption rather than a gross-margin-led story. The less visible shift is cash conversion: FY2025 operating cash flow reached $37.8M despite a $25.5M net loss, so reported loss and near-term cash movement are no longer telling the same story.

Total equity rose from $59.1M in FY2024 to $114.8M in FY2025, rebuilding part of the balance-sheet cushion after the prior year’s compression. Debt-to-equity fell from 9.1x to 4.3x, showing repair even though leverage remains elevated relative to the enlarged equity base.

Gross margin stayed broadly stable, so the major change occurred below gross profit. Operating margin improved from -138.9% to -12.8%, indicating revenue scale absorbed operating costs faster than they grew.

Financial Health Signals

Financial Health Score 71/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Travere Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Travere Therapeutics, Inc. held $322.8M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $37.8M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Travere Therapeutics, Inc. scores 86/100 among other emerging companies.

Dilution

Travere Therapeutics, Inc. had 92M shares outstanding at the end of fiscal year 2025, against 89M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Travere Therapeutics, Inc. scores 48/100 among other emerging companies.

R&D Intensity

Travere Therapeutics, Inc. spent $206.0M on research and development in fiscal year 2025, which was 37.2% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Travere Therapeutics, Inc. scores 68/100 among other emerging companies.

Revenue Progress

Travere Therapeutics, Inc. reported revenue of $490.7M in fiscal year 2025, against $233.2M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Travere Therapeutics, Inc. scores 84/100 among other emerging companies.

Burn Trend

Travere Therapeutics, Inc.'s operations generated $37.8M of cash in fiscal year 2025, against $237.5M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Travere Therapeutics, Inc. scores 89/100 among other emerging companies.

Balance Sheet

Travere Therapeutics, Inc.'s cash, cash equivalents and investments came to $322.8M at the end of fiscal year 2025, against $490.4M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Travere Therapeutics, Inc. scores 49/100 among other emerging companies.

Altman Z-Score Safe

4.17

Travere Therapeutics, Inc. scores 4.17, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($5.4B) relative to total liabilities ($490.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

6/8

Travere Therapeutics, Inc. passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

N/A

Travere Therapeutics, Inc. reported a net loss of $25.5M while generating $37.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Travere Therapeutics, Inc. reported an operating loss of $62.8M against $10.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$169.6M

YoY+48.2%

QoQ+33.3%

Travere Therapeutics, Inc. generated $169.6M in revenue in Q2 2026. This represents an increase of 48.2% from the same quarter a year earlier. Against the prior quarter it is up 33.3%.

EBITDA

$8.2M

YoY+499.4%

QoQ+170.0%

Travere Therapeutics, Inc.'s EBITDA was $8.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 499.4% from the same quarter a year earlier. Against the prior quarter it is up 170.0%.

Net Income

-$34.8M

YoY-172.8%

QoQ+6.2%

Travere Therapeutics, Inc. reported -$34.8M in net income in Q2 2026. This represents a decrease of 172.8% from the same quarter a year earlier. Against the prior quarter it is up 6.2%.

EPS (Diluted)

-$0.37

YoY-164.3%

QoQ+7.5%

Travere Therapeutics, Inc. earned -$0.37 per diluted share (EPS) in Q2 2026. This represents a decrease of 164.3% from the same quarter a year earlier. Against the prior quarter it is up 7.5%.

Cash & Balance Sheet

Cash & Debt

$117.7M

YoY+56.7%

QoQ+50.2%

5Y CAGR+7.2%

10Y CAGR+18.7%

Travere Therapeutics, Inc. held $117.7M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

94M

YoY+5.7%

QoQ+1.4%

5Y CAGR+9.2%

10Y CAGR+9.9%

Travere Therapeutics, Inc. had 94M shares outstanding in Q2 2026. This represents an increase of 5.7% from the same quarter a year earlier. Against the prior quarter it is up 1.4%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

98.7%

YoY0.0pp

QoQ+0.2pp

Travere Therapeutics, Inc.'s gross margin was 98.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. That is unchanged from the same quarter a year earlier. Against the prior quarter it is up 0.2 percentage points.

Operating Margin

2.3%

YoY+13.4pp

QoQ+31.4pp

Travere Therapeutics, Inc.'s operating margin was 2.3% in Q2 2026, reflecting core business profitability. This is up 13.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 31.4 percentage points.

Net Margin

-20.5%

YoY-9.4pp

QoQ+8.7pp

Travere Therapeutics, Inc.'s net profit margin was -20.5% in Q2 2026, showing the share of revenue converted to profit. This is down 9.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.7 percentage points.

Return on Equity

-141.9%

YoY-103.0pp

QoQ-104.3pp

Travere Therapeutics, Inc.'s ROE was -141.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 103.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 104.3 percentage points.

Capital Allocation

R&D Spending

$60.3M

YoY+22.1%

QoQ+5.6%

Travere Therapeutics, Inc. invested $60.3M in research and development in Q2 2026. This represents an increase of 22.1% from the same quarter a year earlier. Against the prior quarter it is up 5.6%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

TVTX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TVTX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1210-K
Revenue	$591.3M	$490.7M+110.5%	$233.2M+60.5%	$145.2M+32.7%	$109.5M-17.0%	$131.8M-33.5%	$198.3M+13.1%	$175.3M+6.8%	$164.2M+6.0%	$154.9M+16.0%	$133.6M+33.7%	$99.9M+254.2%	$28.2M	$0	N/A	$0
Cost of Revenue	$8.3M	$10.3M+33.5%	$7.7M-32.4%	$11.4M+159.0%	$4.4M+15.8%	$3.8M-37.7%	$6.1M+17.0%	$5.2M-5.3%	$5.5M+53.3%	$3.6M-20.8%	$4.6M+108.4%	$2.2M+282.7%	$571K	$0	N/A	N/A
Gross Profit	$583.1M	$480.4M+113.1%	$225.4M+68.5%	$133.8M+27.4%	$105.0M-17.9%	$128.0M-33.4%	$192.2M+13.0%	$170.1M+7.2%	$158.7M+4.9%	$151.3M+17.3%	$129.0M+32.1%	$97.7M+253.6%	$27.6M	$0	N/A	N/A
R&D Expenses	$227.1M	$206.0M-5.3%	$217.5M-11.2%	$245.0M+3166.5%	$7.5M-96.3%	$201.2M+52.7%	$131.8M-6.5%	$141.0M+13.9%	$123.8M+58.3%	$78.2M+10.4%	$70.8M+40.4%	$50.4M+5.5%	$47.8M+574.7%	$7.1M+969.3%	$663K	N/A
SG&A Expenses	$390.6M	$337.2M+27.7%	$264.1M-0.5%	$265.5M+34.4%	$197.5M+56.4%	$126.3M-7.0%	$135.8M+5.3%	$129.0M+24.4%	$103.7M+2.3%	$101.3M+10.2%	$91.9M+15.6%	$79.5M+33.4%	$59.6M+237.2%	$17.7M	N/A	$13K
Operating Income	-$40.5M	-$62.8M+80.6%	-$323.8M+16.6%	-$388.1M-21.4%	-$319.8M-60.4%	-$199.4M-13.2%	-$176.2M-28.2%	-$137.4M-71.6%	-$80.0M-48.8%	-$53.8M+7.6%	-$58.2M-14.7%	-$50.7M+36.4%	-$79.8M-222.2%	-$24.8M	N/A	N/A
EBITDA	N/A	-$2.1M+99.3%	-$280.3M+19.8%	-$349.6M-16.9%	-$299.1M-60.2%	-$186.7M-23.2%	-$151.6M-29.6%	-$117.0M-90.6%	-$61.4M-70.5%	-$36.0M+14.5%	-$42.1M-12.6%	-$37.4M+49.8%	-$74.4M-203.0%	-$24.6M	N/A	N/A
Interest Expense	$9.5M	$10.7M-3.9%	$11.2M-1.0%	$11.3M+2.7%	$11.0M-44.2%	$19.7M+3.1%	$19.1M+1.6%	$18.8M+91.6%	$9.8M+121.8%	$4.4M-6.6%	$4.7M-38.5%	$7.7M+4.1%	$7.4M	$0-100.0%	$84K	N/A
Income Tax	$605K	$988K+723.3%	$120K-46.2%	$223K-28.8%	$313K-23.5%	$409K+102.1%	-$19.4M-92085.7%	-$21K-102.6%	$811K-40.7%	$1.4M+114.1%	-$9.7M+17.8%	-$11.8M-378.5%	-$2.5M-3336.8%	$76K	N/A	N/A
Net Income	-$43.5M	-$25.5M+92.1%	-$321.5M-188.6%	-$111.4M+60.0%	-$278.5M-54.6%	-$180.1M-6.3%	-$169.4M-15.7%	-$146.4M-42.6%	-$102.7M-71.9%	-$59.7M-24.7%	-$47.9M-140.9%	$117.2M+205.7%	-$110.9M-220.4%	-$34.6M	N/A	-$15K
EPS (Basic)	N/A	-$0.29+92.9%	-$4.08-172.0%	-$1.50+65.7%	-$4.37-45.2%	-$3.01+15.4%	-$3.56-2.9%	-$3.46-36.2%	-$2.54-64.9%	-$1.54-19.4%	-$1.29-137.0%	$3.49+178.8%	-$4.43-81.6%	-$2.44	N/A	N/A
EPS (Diluted)	-$0.46	-$0.29+92.9%	-$4.08-172.0%	-$1.50+65.7%	-$4.37-45.2%	-$3.01+15.4%	-$3.56-2.9%	-$3.46-36.2%	-$2.54-64.9%	-$1.54-19.4%	-$1.29-140.7%	$3.17+171.6%	-$4.43	-$2.44	N/A	N/A
Diluted Shares (Avg)	N/A	89M+13.1%	79M+6.2%	74M+16.5%	64M+6.6%	60M+25.9%	48M+12.3%	42M+4.7%	40M+4.3%	39M+1.3%	38M+1.9%	38M+50.0%	25M	14M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$169.6M+48.2%	$127.2M+55.6%	$129.7M+73.4%	$164.9M+162.1%	$114.4M+111.5%	$81.7M+97.5%	$74.8M+66.0%	$62.9M+69.6%
Cost of Revenue	$2.2M+42.9%	$1.9M-58.3%	$2.6M0.0%	$1.6M-2.5%	$1.5M-26.2%	$4.7M+211.1%	$2.6M	$1.6M+26.1%
Gross Profit	$167.4M+48.2%	$125.2M+62.5%	$127.1M+76.0%	$163.3M+166.5%	$112.9M+116.9%	$77.1M+93.3%	$72.2M	$61.3M+71.1%
R&D Expenses	$60.3M+22.1%	$57.1M+21.8%	$57.9M-6.8%	$51.9M+0.4%	$49.4M-9.1%	$46.9M-5.1%	$62.1M	$51.7M-14.7%
SG&A Expenses	$96.1M+53.6%	$80.3M+32.8%	$127.8M+83.8%	$86.5M+31.7%	$62.6M-3.4%	$60.4M-5.9%	$69.5M	$65.6M-3.2%
Operating Income	$4.0M+131.3%	-$36.9M+13.5%	-$32.4M+46.6%	$24.9M+144.4%	-$12.7M+81.3%	-$42.7M+69.4%	-$60.7M+35.5%	-$56.1M+39.4%
EBITDA	$8.2M+499.4%	-$11.7M+60.8%	-$14.3M+70.6%	$40.7M+190.7%	$1.4M+102.4%	-$29.9M+76.9%	-$48.6M+42.6%	-$44.9M+44.6%
Interest Expense	$2.1M-25.0%	$2.3M-19.5%	$2.3M-18.6%	$2.8M-0.9%	$2.8M+2.1%	$2.9M+2.0%	$2.8M	$2.8M-0.8%
Income Tax	-$204K-1120.0%	-$120K-407.7%	$921K+1379.2%	$8K+109.5%	$20K-76.5%	$39K-79.6%	-$72K	-$84K-800.0%
Net Income	-$34.8M-172.8%	-$37.1M+10.0%	$2.7M+104.5%	$25.7M+146.9%	-$12.8M+81.9%	-$41.2M+69.7%	-$60.3M+33.2%	-$54.8M-136.4%
EPS (Basic)	-$0.37-164.3%	-$0.40+14.9%	$0.03+104.2%	$0.29+141.4%	-$0.14+84.6%	-$0.47+73.3%	-$0.71+39.8%	-$0.70-135.5%
EPS (Diluted)	-$0.37-164.3%	-$0.40+14.9%	$0.03+104.2%	$0.28+140.0%	-$0.14+84.6%	-$0.47+73.3%	-$0.71+39.8%	-$0.70-135.5%
Diluted Shares (Avg)	93M+5.1%	92M+4.0%	N/A	103M+31.9%	89M+14.8%	88M+14.5%	N/A	78M+1.9%

TVTX Balance Sheet

TVTX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1210-K
Total Assets	$605.2M+1.9%	$594.1M-24.7%	$788.9M+17.3%	$672.6M-13.4%	$776.6M+27.9%	$607.4M+0.4%	$604.8M-14.7%	$709.2M+36.3%	$520.3M-0.9%	$525.3M+2.5%	$512.3M+278.1%	$135.5M+560.9%	$20.5M+757.2%	$2.4M	$4K
Current Assets	$437.6M+5.0%	$416.7M-32.4%	$616.8M+26.8%	$486.4M-16.5%	$582.8M+42.0%	$410.4M-4.3%	$429.1M-13.4%	$495.7M+52.1%	$325.8M-2.0%	$332.4M+10.1%	$301.9M+708.7%	$37.3M+397.7%	$7.5M+22481.9%	$33K	$4K
Cash & Equivalents	$93.0M+58.9%	$58.5M+0.6%	$58.2M-5.7%	$61.7M-62.8%	$165.8M+95.5%	$84.8M+35.8%	$62.4M-39.3%	$102.9M+3.5%	$99.4M+142.4%	$41.0M+8.5%	$37.8M+107.7%	$18.2M+203.6%	$6.0M+54418.2%	$11K	$1K
Short-Term Investments	$145.4M	$0-100.0%	$248.6M-12.9%	$285.5M+8.9%	$262.2M-3.5%	$271.8M+29.7%	$209.5M+0.5%	$208.5M+69.1%	$123.3M-42.6%	$214.9M+12.0%	$191.8M+1907.1%	$9.6M+7085.3%	$133K	$0	$0
Inventory	$36.2M-13.6%	$41.9M+344.8%	$9.4M+108.0%	$4.5M-38.2%	$7.3M-3.9%	$7.6M+25.1%	$6.1M+8.2%	$5.6M+5.0%	$5.4M+89.3%	$2.8M+11.4%	$2.5M+216.6%	$801K	N/A	N/A	N/A
Accounts Receivable	$80.1M+195.5%	$27.1M+28.0%	$21.2M+27.2%	$16.6M+4.6%	$15.9M-0.1%	$15.9M-11.8%	$18.0M+42.5%	$12.7M-8.7%	$13.9M-25.1%	$18.5M+48.6%	$12.5M+56.5%	$8.0M	N/A	N/A	N/A
Long-Term Investments	$84.4M	$0-100.0%	$260.0M+152.4%	$103.0M-17.5%	$124.9M+2390.4%	$5.0M-96.0%	$126.6M-21.0%	$160.2M+105.5%	$78.0M	$0	$0	$0	$0	$0	$0
Goodwill	N/A	$800K0.0%	$800K0.0%	$800K-11.1%	$900K0.0%	$900K-3.8%	$936K0.0%	$936K0.0%	$936K0.0%	$936K0.0%	$936K0.0%	$936K	N/A	N/A	N/A
Total Liabilities	$490.4M-8.4%	$535.0M-9.0%	$588.1M-6.6%	$629.7M+32.7%	$474.5M+19.8%	$396.2M+3.3%	$383.6M-1.9%	$390.9M+72.0%	$227.2M+4.5%	$217.5M+2.5%	$212.3M+22.9%	$172.7M+330.0%	$40.2M+592.6%	$5.8M	$67K
Current Liabilities	$159.9M-20.3%	$200.8M+12.8%	$177.9M+25.1%	$142.2M+14.6%	$124.1M+33.9%	$92.7M-2.9%	$95.4M-8.8%	$104.6M+22.1%	$85.7M+2.9%	$83.3M-4.3%	$87.0M-19.1%	$107.5M+194.1%	$36.6M+530.5%	$5.8M	$67K
Non-Current Liabilities	$330.5M-1.1%	$334.3M-18.5%	$410.2M-15.9%	$487.6M+39.1%	$350.4M+15.4%	$303.6M+5.3%	$288.2M+0.7%	$286.3M+102.3%	$141.5M+5.4%	$134.3M+7.1%	$125.3M+92.2%	$65.2M+1710.2%	$3.6M	$0	$0
Total Equity	$114.8M+94.4%	$59.1M-70.6%	$200.8M+368.6%	$42.9M-85.8%	$302.1M+43.0%	$211.2M-4.5%	$221.2M-30.5%	$318.3M+8.6%	$293.1M-4.8%	$307.8M+2.6%	$300.0M+905.3%	-$37.3M-89.4%	-$19.7M-477.1%	-$3.4M	-$63K
Retained Earnings	-$1.5B-1.8%	-$1.4B-28.6%	-$1.1B-11.0%	-$1.0B-32.4%	-$766.0M-30.7%	-$585.9M-40.7%	-$416.4M-54.2%	-$270.0M-52.0%	-$177.7M-57.1%	-$113.1M-73.5%	-$65.2M+63.6%	-$179.2M-162.6%	-$68.2M-103.0%	-$33.6M	-$136K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$799.4M+43.9%	$555.2M+1.2%	$605.2M+1.9%	$538.6M+6.8%	$555.3M+0.8%	$548.8M-17.3%	$594.1M-24.7%	$504.4M-39.4%
Current Assets	$615.1M+62.1%	$392.7M+4.9%	$437.6M+5.0%	$371.1M+14.3%	$379.6M+2.9%	$374.2M-22.2%	$416.7M-32.4%	$324.7M-52.7%
Cash & Equivalents	$117.7M+56.7%	$78.4M+26.6%	$93.0M+58.9%	$110.9M+204.7%	$75.2M+132.7%	$61.9M+43.1%	$58.5M+0.6%	$36.4M-74.8%
Short-Term Investments	$175.9M	$130.6M	$145.4M	$138.7M-36.7%	$0-100.0%	$0-100.0%	$0-100.0%	$218.9M+3.0%
Inventory	$40.0M+6.3%	$37.1M-2.5%	$36.2M-13.6%	$37.5M-12.4%	$37.7M-12.3%	$38.0M-10.2%	$41.9M+344.8%	$42.9M+106.4%
Accounts Receivable	$80.6M+108.3%	$87.3M+153.9%	$80.1M+195.5%	$83.0M+229.7%	$38.7M+58.3%	$34.4M+51.3%	$27.1M+28.0%	$25.2M+72.8%
Long-Term Investments	$195.5M	$55.7M	$84.4M	$4.9M-77.6%	$0-100.0%	$0-100.0%	$0-100.0%	$22.1M-92.0%
Goodwill	N/A	N/A	N/A	$800K0.0%	$800K0.0%	$800K0.0%	$800K0.0%	$800K0.0%
Total Liabilities	$774.8M+48.3%	$456.5M-11.5%	$490.4M-8.4%	$465.0M-13.1%	$522.6M-2.5%	$516.0M-12.5%	$535.0M-9.0%	$534.9M-3.3%
Current Liabilities	$152.0M-19.8%	$125.4M-31.3%	$159.9M-20.3%	$135.1M-28.9%	$189.5M+56.3%	$182.5M+5.3%	$200.8M+12.8%	$190.0M+36.3%
Non-Current Liabilities	$622.8M+87.0%	$331.0M-0.7%	$330.5M-1.1%	$329.9M-4.3%	$333.0M-19.7%	$333.5M-19.9%	$334.3M-18.5%	$344.8M-16.6%
Total Equity	$24.5M-25.1%	$98.7M+200.8%	$114.8M+94.4%	$73.6M+341.6%	$32.7M+116.2%	$32.8M-55.7%	$59.1M-70.6%	-$30.5M-110.9%
Retained Earnings	-$1.5B-2.9%	-$1.5B-1.4%	-$1.5B-1.8%	-$1.5B-6.4%	-$1.5B-12.7%	-$1.5B-18.0%	-$1.4B-28.6%	-$1.4B-33.9%

Not reported in any period shown, so not listed: Long-Term Debt.

TVTX Cash Flow Statement

TVTX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1210-K
Operating Cash Flow	$92.7M	$37.8M+115.9%	-$237.5M+15.2%	-$280.0M-50.3%	-$186.3M-1159.4%	-$14.8M+65.4%	-$42.7M+26.6%	-$58.2M-133.2%	-$25.0M-437.1%	$7.4M+315.1%	-$3.4M-147.7%	-$1.4M+97.0%	-$45.9M-160.7%	-$17.6M-542.7%	-$2.7M	-$49
Depreciation & Amortization	N/A	$60.7M+39.5%	$43.6M+13.0%	$38.5M+86.0%	$20.7M+62.6%	$12.7M-48.1%	$24.6M+20.4%	$20.4M+9.3%	$18.7M+4.9%	$17.8M+10.3%	$16.1M+20.5%	$13.4M+148.0%	$5.4M+2400.5%	$216K+73.0%	$125K	N/A
Stock-Based Compensation	N/A	$44.9M+21.6%	$36.9M-16.6%	$44.2M+16.0%	$38.1M+29.0%	$29.6M+25.2%	$23.6M+11.9%	$21.1M+6.7%	$19.8M-26.4%	$26.9M-7.7%	$29.1M+12.4%	$25.9M+62.9%	$15.9M+192.1%	$5.4M-75.7%	$22.4M	N/A
Capital Expenditures	N/A	N/A	N/A	$668K+249.7%	$191K-96.3%	$5.1M-24.6%	$6.8M+3370.3%	$195K-73.2%	$727K-18.0%	$887K-37.9%	$1.4M+6390.9%	$22K-96.7%	$663K+466.7%	$117K+372.3%	$25K	N/A
Free Cash Flow	N/A	N/A	N/A	-$280.7M-50.5%	-$186.5M-837.4%	-$19.9M+59.8%	-$49.5M+15.2%	-$58.4M-127.4%	-$25.7M-494.2%	$6.5M+233.8%	-$4.9M-245.1%	-$1.4M+97.0%	-$46.5M-162.7%	-$17.7M-541.2%	-$2.8M	N/A
Investing Cash Flow	-$203.0M	$27.9M-71.9%	$99.3M+78.1%	$55.8M+271.3%	-$32.6M+76.3%	-$137.6M-124.4%	-$61.3M-408.7%	$19.9M+109.8%	-$203.3M-545.8%	$45.6M+339.7%	$10.4M+112.9%	-$80.6M	N/A	-$5.4M-218.1%	-$1.7M	N/A
Financing Cash Flow	$153.1M	-$33.5M-124.0%	$139.4M-36.3%	$218.8M+86.1%	$117.6M-49.3%	$231.7M+81.4%	$127.7M+6248.9%	-$2.1M-100.9%	$231.9M+4158.3%	$5.4M+241.5%	-$3.8M-103.8%	$101.6M+6.6%	$95.3M+228.9%	$29.0M+553.1%	$4.4M	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$2.3M+135.6%	$958K	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$58.1M+1065.4%	-$40.4M+4.3%	$60.7M+269.9%	$14.3M+133.7%	$5.0M+112.4%	-$42.2M+64.5%	-$35.7M+49.3%	-$42.5M+28.1%
Depreciation & Amortization	$4.2M-69.8%	$25.2M+96.9%	$18.1M+50.0%	$15.8M+40.5%	$14.0M+35.5%	$12.8M+29.6%	$12.1M+27.4%	$11.2M-2.1%
Stock-Based Compensation	$21.8M+104.6%	$16.1M+40.5%	N/A	$11.3M+40.4%	$10.6M+7.3%	$11.5M+17.8%	N/A	$8.0M-29.1%
Capital Expenditures	N/A	N/A	N/A	$140K	N/A	N/A	N/A	$0-100.0%
Free Cash Flow	N/A	N/A	N/A	$14.2M+133.4%	N/A	N/A	N/A	-$42.5M+28.1%
Investing Cash Flow	-$206.3M-4353.3%	$21.5M-47.8%	-$104.8M-30.5%	$86.6M+87.7%	$4.8M-83.0%	$41.3M-60.6%	-$80.3M-373.8%	$46.1M-65.4%
Financing Cash Flow	$187.5M+12613.0%	$4.2M+13.1%	$26.7M-80.8%	-$65.3M-142141.3%	$1.5M+88.6%	$3.7M+808.2%	$139.1M+112092.7%	$46K+107.3%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

TVTX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TVTX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1210-K
Gross Margin	97.9%+1.2pp	96.7%+4.6pp	92.1%-3.8pp	96.0%-1.1pp	97.1%+0.2pp	96.9%-0.1pp	97.0%+0.4pp	96.6%-1.0pp	97.7%+1.1pp	96.6%-1.2pp	97.8%-0.2pp	98.0%	N/A	N/A	N/A
Operating Margin	-12.8%	-138.9%	-267.2%	-292.2%	-151.3%	-88.8%-10.5pp	-78.3%-29.6pp	-48.7%-14.0pp	-34.7%+8.9pp	-43.6%+7.2pp	-50.8%	-283.0%	N/A	N/A	N/A
Net Margin	-5.2%	-137.9%	-76.7%	-254.4%	-136.6%	-85.4%-1.9pp	-83.5%-21.0pp	-62.5%-24.0pp	-38.6%-2.7pp	-35.9%	117.4%	-393.4%	N/A	N/A	N/A
Return on Equity	-22.3%+522.0pp	-544.3%-488.8pp	-55.5%+594.4pp	-649.9%-590.3pp	-59.6%+20.6pp	-80.2%-14.0pp	-66.2%-33.9pp	-32.3%-11.9pp	-20.4%-4.8pp	-15.6%-54.6pp	39.1%	N/A	N/A	N/A	N/A
Return on Assets	-4.2%+49.9pp	-54.1%-40.0pp	-14.1%+27.3pp	-41.4%-18.2pp	-23.2%+4.7pp	-27.9%-3.7pp	-24.2%-9.7pp	-14.5%-3.0pp	-11.5%-2.4pp	-9.1%-32.0pp	22.9%+104.8pp	-81.9%+87.0pp	-168.9%	N/A	-379.3%
Current Ratio	2.74+0.7x	2.08-1.4x	3.470.0x	3.42-1.3x	4.70+0.3x	4.43-0.1x	4.50-0.2x	4.74+0.9x	3.80-0.2x	3.99+0.5x	3.47+3.1x	0.35+0.1x	0.21+0.2x	0.01	0.06
Debt-to-Equity	4.27-4.8x	9.06+6.1x	2.93-11.8x	14.70+13.1x	1.57-0.3x	1.88+0.1x	1.73+0.5x	1.23+0.5x	0.78+0.1x	0.710.0x	0.71	N/A	N/A	N/A	N/A
Asset Turnover	0.81+0.4x	0.39+0.2x	0.180.0x	0.160.0x	0.17-0.2x	0.330.0x	0.29+0.1x	0.23-0.1x	0.300.0x	0.25+0.1x	0.200.0x	0.21+0.2x	0.00	N/A	0.00
FCF Margin	N/A	N/A	-193.3%	-170.4%	-15.1%+9.9pp	-25.0%+8.4pp	-33.3%-17.7pp	-15.6%-19.9pp	4.2%+7.8pp	-3.6%-2.2pp	-1.4%	-164.9%	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	98.7%0.0pp	98.5%+4.2pp	98.0%+1.4pp	99.0%+1.6pp	98.7%+2.5pp	94.3%-2.1pp	96.6%	97.4%+0.9pp
Operating Margin	2.3%+13.4pp	-29.0%+23.2pp	-25.0%+56.2pp	15.1%+104.4pp	-11.1%	-52.2%	-81.2%	-89.3%
Net Margin	-20.5%-9.4pp	-29.2%+21.3pp	2.1%+82.7pp	15.6%+102.7pp	-11.1%	-50.4%	-80.6%	-87.1%
Return on Equity	-141.9%-103.0pp	-37.6%+88.0pp	2.4%+104.4pp	34.9%	-39.0%+425.9pp	-125.6%+58.1pp	-102.0%-57.1pp	N/A
Return on Assets	-4.3%-2.0pp	-6.7%+0.8pp	0.4%+10.6pp	4.8%+15.6pp	-2.3%+10.5pp	-7.5%+13.0pp	-10.1%+1.3pp	-10.9%-29.0pp
Current Ratio	4.05+2.0x	3.13+1.1x	2.74+0.7x	2.75+1.0x	2.00-1.0x	2.05-0.7x	2.08-1.4x	1.71-3.2x
Debt-to-Equity	31.60+15.6x	4.62-11.1x	4.27-4.8x	6.32	15.96-19.4x	15.72+7.8x	9.06+6.1x	N/A
Asset Turnover	0.210.0x	0.23+0.1x	0.21+0.1x	0.31+0.2x	0.21+0.1x	0.15+0.1x	0.13+0.1x	0.12+0.1x
FCF Margin	N/A	N/A	N/A	8.6%+76.2pp	N/A	N/A	N/A	-67.6%

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Travere Therapeutics, Inc. TVTX	FY2025	$490.7M	-$25.5M	-5.2%	$5.4B	71/100
Amicus Therapeutics, Inc FOLD	FY2025	$634.2M	-$27.1M	-4.3%	$4.5B	44/100
Agios Pharmaceuticals, Inc. AGIO	FY2025	$54.0M	-$413.0M	N/A	$1.9B	70/100
Belite Bio, Inc BLTE	FY2025	N/A	-$77.6M	N/A	$6.6B	—
Apogee Therapeutics, Inc. APGE	FY2025	N/A	-$255.8M	N/A	$10.2B	—
Tarsus Pharmaceuticals, Inc. TARS	FY2025	$451.4M	-$66.0M	-14.6%	$3.5B	49/100

Where Travere Therapeutics, Inc. Ranks

Frequently Asked Questions

What is Travere Therapeutics, Inc.'s annual revenue?

Travere Therapeutics, Inc. (TVTX) reported $490.7M in total revenue for fiscal year 2025. This represents a 110.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Travere Therapeutics, Inc.'s revenue growing?

Travere Therapeutics, Inc. (TVTX) revenue grew by 110.5% year-over-year, from $233.2M to $490.7M in fiscal year 2025.

Is Travere Therapeutics, Inc. profitable?

No, Travere Therapeutics, Inc. (TVTX) reported a net income of -$25.5M in fiscal year 2025, with a net profit margin of -5.2%.

What is Travere Therapeutics, Inc.'s EBITDA?

Travere Therapeutics, Inc. (TVTX) had EBITDA of -$2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Travere Therapeutics, Inc.'s gross margin?

Travere Therapeutics, Inc. (TVTX) had a gross margin of 97.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Travere Therapeutics, Inc.'s operating margin?

Travere Therapeutics, Inc. (TVTX) had an operating margin of -12.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Travere Therapeutics, Inc.'s net profit margin?

Travere Therapeutics, Inc. (TVTX) had a net profit margin of -5.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Travere Therapeutics, Inc.'s return on equity (ROE)?

Travere Therapeutics, Inc. (TVTX) has a return on equity of -22.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Travere Therapeutics, Inc.'s operating cash flow?

Travere Therapeutics, Inc. (TVTX) generated $37.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Travere Therapeutics, Inc.'s total assets?

Travere Therapeutics, Inc. (TVTX) had $605.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Travere Therapeutics, Inc. spend on research and development?

Travere Therapeutics, Inc. (TVTX) invested $206.0M in research and development during fiscal year 2025.

How many shares does Travere Therapeutics, Inc. have outstanding?

Travere Therapeutics, Inc. (TVTX) had 92M shares outstanding as of fiscal year 2025.

What is Travere Therapeutics, Inc.'s current ratio?

Travere Therapeutics, Inc. (TVTX) had a current ratio of 2.74 as of fiscal year 2025, which is generally considered healthy.

What is Travere Therapeutics, Inc.'s debt-to-equity ratio?

Travere Therapeutics, Inc. (TVTX) had a debt-to-equity ratio of 4.27 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Travere Therapeutics, Inc.'s return on assets (ROA)?

Travere Therapeutics, Inc. (TVTX) had a return on assets of -4.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Travere Therapeutics, Inc.'s P/E ratio?

Travere Therapeutics, Inc. (TVTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $5.4B as of Oct 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Travere Therapeutics, Inc.'s price-to-sales ratio?

Travere Therapeutics, Inc. (TVTX) trades at 9.1x sales, its market capitalization divided by revenue of $591.3M revenue, trailing 12 months to June 30, 2026. The market capitalization is $5.4B as of Oct 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Travere Therapeutics, Inc.'s Altman Z-Score?

Travere Therapeutics, Inc. (TVTX) has an Altman Z-Score of 4.17, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Travere Therapeutics, Inc.'s Piotroski F-Score?

Travere Therapeutics, Inc. (TVTX) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Travere Therapeutics, Inc.'s earnings high quality?

Travere Therapeutics, Inc. (TVTX) reported a net loss of $25.5M while generating $37.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Travere Therapeutics, Inc. cover its interest payments?

Travere Therapeutics, Inc. (TVTX) reported an operating loss of $62.8M against $10.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Travere Therapeutics, Inc.?

Travere Therapeutics, Inc. (TVTX) scores 71 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.